tag monoclonal-antibodies 
Rethinking Clinical Trials
JANUARY 17, 2024
The first monoclonal antibody (mABs) treatment for treatment of COVID-19 was approved in November 2020. UPMC built upon the success of the Remdesivir lottery and in December 2020, UPMC began infusing monoclonal antibodies across 45 UPMC locations. Many patients did not answer the phone.
Drug Discovery World
JANUARY 10, 2023
For over 50 years, Bethyl Laboratories (now a Fortis Life Sciences brand) has been dedicated to improving lives by supporting scientific discovery through qualified antibody products and custom services. All of our antibodies are highly validated using six pillars of validation, meaning that our antibodies do what we say they’ll do.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
FEBRUARY 22, 2023
The patent battle between Amgen and Sanofi over their cholesterol-lowering antibodies has divided big pharma in the past months. Both drugs are monoclonal antibodies that inhibit the protein PCSK9. Both drugs come with a high price tag. To an extent, the challenge here lies in the nature of antibodies, says Contreras.
pharmaphorum
JANUARY 18, 2022
The hope is that they will harness and re-programme natural cellular mechanisms to selectively remove the disease driving proteins from human tissues, working by boosting interactions – gluing – between therapeutically relevant proteins and the machinery used by cells to naturally tag and destroy proteins.
XTalks
APRIL 18, 2024
Previously, Roche secured an FDA breakthrough tag for another one of its Alzheimer’s blood tests that detects levels of pTau-181 and ApoE4 (apolipoprotein e4). However, the guidance doesn’t say whether it could serve as a study’s primary endpoint on its own.
pharmaphorum
DECEMBER 23, 2022
There’s been huge progress in treatments for blood cancer in recent years – but drawbacks of expensive CAR-T cell and injected antibody therapies have led drug developers to look at novel oral therapies as patient-friendly alternatives. Oral therapy data presented at ASH. CellCentric, a U.K-based
XTalks
JUNE 9, 2021
Aducanumab is a human IgG1 monoclonal antibody that binds to aggregated forms of amyloid beta to help reduce its buildup. Aducanumab Controversy and Price Tag. Biogen developed aducanumab in partnership with Japanese pharmaceutical company Eisai. Evidence for aducanumab’s efficacy has been highly contested.
Expert insights. Personalized for you.
169 
Let's personalize your content